CO2020008885A2 - Arilsulfatasa a purificada y composiciones de la misma - Google Patents

Arilsulfatasa a purificada y composiciones de la misma

Info

Publication number
CO2020008885A2
CO2020008885A2 CONC2020/0008885A CO2020008885A CO2020008885A2 CO 2020008885 A2 CO2020008885 A2 CO 2020008885A2 CO 2020008885 A CO2020008885 A CO 2020008885A CO 2020008885 A2 CO2020008885 A2 CO 2020008885A2
Authority
CO
Colombia
Prior art keywords
compositions
arylsulfatase
purified arylsulfatase
purified
mld
Prior art date
Application number
CONC2020/0008885A
Other languages
English (en)
Inventor
Andrew Keefe
George Enriquez
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CO2020008885A2 publication Critical patent/CO2020008885A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona, entre otras cosas, métodos de tratamiento de la Enfermedad de Leucodistrofia Metacromática (MLD) y composiciones que comprenden la proteína arilsulfatasa A (ASA) recombinante mediante el uso de terapia de reemplazo de enzimas.
CONC2020/0008885A 2017-12-19 2020-07-17 Arilsulfatasa a purificada y composiciones de la misma CO2020008885A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762607831P 2017-12-19 2017-12-19
US201762608569P 2017-12-20 2017-12-20
US201862625814P 2018-02-02 2018-02-02
US201862760597P 2018-11-13 2018-11-13
PCT/US2018/066583 WO2019126376A1 (en) 2017-12-19 2018-12-19 Purified arylsulfatase a and compositons thereof

Publications (1)

Publication Number Publication Date
CO2020008885A2 true CO2020008885A2 (es) 2020-10-30

Family

ID=65024076

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008885A CO2020008885A2 (es) 2017-12-19 2020-07-17 Arilsulfatasa a purificada y composiciones de la misma

Country Status (12)

Country Link
US (1) US20200384089A1 (es)
EP (1) EP3728572A1 (es)
JP (2) JP2021508322A (es)
KR (1) KR20200107984A (es)
CN (1) CN111699249A (es)
AU (1) AU2018393045A1 (es)
BR (1) BR112020012637A2 (es)
CA (1) CA3086181A1 (es)
CO (1) CO2020008885A2 (es)
MX (1) MX2020006477A (es)
RU (1) RU2020123718A (es)
WO (1) WO2019126376A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
PL2585104T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania arylosulfatazy a do oun
WO2014110246A1 (en) * 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
WO2017143233A1 (en) * 2016-02-17 2017-08-24 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a

Also Published As

Publication number Publication date
MX2020006477A (es) 2020-12-10
US20200384089A1 (en) 2020-12-10
BR112020012637A2 (pt) 2020-12-01
AU2018393045A1 (en) 2020-07-02
EP3728572A1 (en) 2020-10-28
CA3086181A1 (en) 2019-06-27
JP2021508322A (ja) 2021-03-04
CN111699249A (zh) 2020-09-22
WO2019126376A1 (en) 2019-06-27
RU2020123718A (ru) 2022-01-20
KR20200107984A (ko) 2020-09-16
JP2023165991A (ja) 2023-11-17

Similar Documents

Publication Publication Date Title
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112021024830A2 (pt) Vesículas extracelulares microbianas processadas
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CO2022000481A2 (es) Inhibidores de enzimas
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
CO2021003136A2 (es) Terapias de combinación
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.